文献速递关节外科

比较医疗保险与非医疗保险住院全髋关节置换术:新CMS患者报告结局绩效措施是否适用于所有人群?

Comparing Medicare and Non-Medicare Inpatient Total Hip Arthroplasty: Is the New Centers for Medicare & Medicaid Services Patient-Reported Outcomes Performance Measure Mandate Applicable to All?
PubMed 文献 · J Arthroplasty · 2026-03-11

本研究分析2016至2023年3240例全髋关节置换术患者,按保险类型分层。医疗保险患者年龄更大、合并症更多,但实现SCB的比例与非医疗保险患者相当或更优。商业保险反而与更高的SCB失败几率相关。

要点

  • 医疗保险患者实现SCB的比例与非医疗保险患者相当或更优。
  • 商业保险患者SCB失败几率是医疗保险的2.08倍。
  • 非白人种族、更高合并症和基线PROM高于中位数是SCB失败的独立预测因素。

核心结论

  • 医疗保险患者实现SCB的比例与非医疗保险患者相当或更好,提示统一阈值跨保险组应用存在复杂性,需要细化调整。

研究设计与样本

  • 前瞻性收集的队列研究,纳入2016至2023年3240例全髋关节置换术患者,按保险类型分为医疗保险组(n=2108)、商业保险组(n=921)和医疗补助组(n=211)。

主要发现

  • 医疗保险患者年龄更大(中位72岁 vs 60-61岁,P<0.001),BMI更低(中位29 vs 31-31.1,P<0.001),合并症更多,Charlson合并症指数≥2者超过40%而非医疗保险患者低于23%(P<0.001)。
  • 医疗保险患者基线残疾程度低于医疗补助患者,但心理健康低于商业保险患者。
  • SCB失败的独立预测因素包括非白人种族(OR=1.37,P=0.028)、更高合并症(OR=1.12,P=0.039)和基线PROM评分高于中位数(OR=3.92,P<0.001)。
  • 与医疗保险相比,商业保险与SCB失败几率增加两倍以上相关(OR=2.08,P=0.001),医疗补助无差异(OR=1.14,P=0.35)。
  • 非医疗保险与医疗保险分组比较无差异(OR=1,P=0.98)。

关键数值与推荐

  • SCB定义为髋关节残疾和骨关节炎结局评分-关节置换版改善22分。

临床怎么用

  • 临床中应认识到商业保险患者SCB失败风险更高,可能需要针对性调整或额外支持。
  • 基线PROM评分高于中位数的患者SCB失败风险显著增加,应加强围手术期管理。

局限性

  • 证据等级为III级,属于回顾性队列分析,可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Centers for Medicare & Medicaid Services implemented the Patient Reported Outcomes Performance Measure policy, mandating reporting of patient-reported outcome measures for total hip arthroplasty. A 22-point improvement in Hip disability and Osteoarthritis Outcome Score for Joint Replacement defines substantial clinical benefit (SCB). However, it remains unclear whether SCB achievement differs across insurance groups. METHODS: We analyzed a prospectively collected cohort of 3,240 total hip arthroplasty patients (2016 to 2023) stratified by insurance: Medicare (n = 2,108), commercial (n = 921), and Medicaid (n = 211). Baseline demographics, comorbidities, and patient-reported outcome measures were compared between Medicare and non-Medicare patients. Multivariable regressions identified predictors of SCB for Hip disability and Osteoarthritis Outcome Score for Joint Replacement. Medicare patients were older (median 72 versus 60 to 61 years, P < 0.001), had lower body mass index (median 29 versus 31 to 31.1, P < 0.001), and greater comorbidity, with over 40% having a Charlson Comorbidity Index ≥ 2 compared to less than 23% in non-Medicare patients (P < 0.001). RESULTS: Medicare patients demonstrated less baseline disability than Medicaid, but lower mental health than commercial patients. Independent predictors of SCB failure included non-White race (odds ratio (OR) = 1.37, P = 0.028), higher comorbidities (OR = 1.12, P = 0.039), and baseline PROM score above the median (OR = 3.92, P < 0.001). Compared with Medicare, commercial insurance was associated with more than twice the odds of SCB failure (OR = 2.08, P = 0.001), while Medicaid showed no difference (OR = 1.14, P = 0.35). A grouped non-Medicare versus Medicare comparison revealed no difference (OR = 1, P = 0.98). CONCLUSIONS: Overall, Medicare patients achieved SCB at rates comparable to or better than non-Medicare patients. These findings highlight the complexity of applying uniform thresholds across insurance groups and underscore the need for refined adjustment. LEVEL OF EVIDENCE: III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Elmenawi KA, Kwas C, Molloy LG, et al. Comparing Medicare and Non-Medicare Inpatient Total Hip Arthroplasty: Is the New Centers for Medicare & Medicaid Services Patient-Reported Outcomes Performance Measure Mandate Applicable to All? J Arthroplasty. 2026. PMID: 41825498. doi:10.1016/j.arth.2026.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。